# A multicentre, randomised, double-blind, placebo-controlled trial to evaluate intravenous infusion of salbutamol versus saline for 28-day mortality in patients with acute respiratory distress syndrome

Submission date	<b>Recruitment status</b> No longer recruiting	[X] Prospectively registered	
14/04/2006		[X] Protocol	
<b>Registration date</b> 07/07/2006	<b>Overall study status</b> Completed	[] Statistical analysis plan	
		[X] Results	
Last Edited	Condition category	[] Individual participant data	
16/09/2013	Respiratory		

**Plain English summary of protocol** Not provided at time of registration

## **Contact information**

**Type(s)** Scientific

**Contact name** Prof Fang Gao

### Contact details

Adult Intensive Care Unit Birmingham Heartlands Hospital Bordesley Green East Birmingham United Kingdom B9 5SS

## Additional identifiers

EudraCT/CTIS number

**IRAS number** 

ClinicalTrials.gov number

**Secondary identifying numbers** Version 2

## Study information

Scientific Title

**Acronym** BALTI-2

**Study objectives** In patients with acute respiratory distress syndrome (ARDS), treatment with intravenous salbutamol will reduce 28-day mortality

**Ethics approval required** Old ethics approval format

**Ethics approval(s)** West Midlands Multicentre Research Ethics Committee, approval pending as of 01/05/2006

**Study design** Randomised, double-blind, placebo-controlled trial

**Primary study design** Interventional

**Secondary study design** Randomised controlled trial

**Study setting(s)** Not specified

**Study type(s)** Treatment

**Participant information sheet** Not available in web format, please use the contact details below to request a patient information sheet

Health condition(s) or problem(s) studied Acute respiratory distress syndrome

**Interventions** Salbutamol or placebo will be administered through a dedicated intravenous line for seven days

Intervention Type

Drug

#### Phase

Not Specified

#### Drug/device/biological/vaccine name(s)

Salbutamol

#### Primary outcome measure

Mortality 28 days after randomisation

#### Secondary outcome measures

- 1. Number of ventilator-free days
- 2. Mortality at (first) discharge from ICU
- 3. Mortality at discharge from hospital
- 4. Mortality at 12 months post randomisation
- 5. ICU length of stay
- 6. Hospital length of stay
- 7. Disability and quality of life at 12 months after randomisation

#### Overall study start date

01/08/2006

#### **Completion date**

01/09/2007

## Eligibility

#### Key inclusion criteria

On day 1 following intensive care unit (ICU) admission, the primary caring ICU clinician should consider all adult patients (age ≥18 years) with severe hypoxaemic respiratory failure (PaO2 /FiO2) ≤26.7 kPa to be eligible for inclusion in the trial

Participant type(s) Patient

**Age group** Adult

**Lower age limit** 18 Years

**Sex** Both

Target number of participants 100

#### Key exclusion criteria

1. Pregnancy

- 2. Cardiogenic pulmonary oedema (confirmed by medical history and chest x-ray)
- 3. Severe obstructive airway disease requiring nebulised or intravenous (IV) beta 2-agonists

- 4. Treatment with beta 2-blockers ≤48 hours
- 5. Brain stem death

6. Treatment withdrawal ≤24 hours, which indicates any interventions (including a trial) would be considered inappropriate

- 7. Refusing consent or patients in whom relatives refuse assent
- 8. Enrolled in another interventional clinical trial in the last 28 days

### Date of first enrolment

01/08/2006

# Date of final enrolment 01/09/2007

## Locations

#### **Countries of recruitment** England

United Kingdom

**Study participating centre Adult Intensive Care Unit** Birmingham United Kingdom B9 5SS

## Sponsor information

**Organisation** Heart of England NHS Foundation Trust (UK)

**Sponsor details** Birmingham Heartlands Hospital Bordesley Green East Birmingham England United Kingdom B9 5SS

**Sponsor type** Hospital/treatment centre

## Funder(s)

**Funder type** Research organisation

Funder Name Intensive Care Society

Alternative Name(s) ICS

**Funding Body Type** Private sector organisation

**Funding Body Subtype** Associations and societies (private and public)

**Location** United Kingdom

## **Results and Publications**

#### Publication and dissemination plan

Not provided at time of registration

Intention to publish date

#### Individual participant data (IPD) sharing plan

#### IPD sharing plan summary

Not provided at time of registration

#### Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<u>Protocol article</u>	protocol	09/05/2011		Yes	No
<u>Results article</u>	results	21/01/2012		Yes	No
Results article	results	01/09/2013		Yes	No